At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Vesatolimod +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Study to Evaluate the Safety and Tolerability of a Regimen of Dual Anti-HIV Envelope Antibodies, VRC07-523LS and CAP256V2LS, in a Sequential Regimen With a TLR7 Agonist, Vesatolimod, in Early Antiretroviral-Treated HIV-1 Clade C-Infected Women
In Brief
A Phase 2 clinical trial evaluating Vesatolimod, VRC07523LS, and 1 other intervention for HIV-1-infection. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The goals of this clinical study are to learn more about the study drugs, VRC07-523LS, CAP256V2LS, and vesatolimod (VES) and how safe it is in women that have HIV and are on antiretroviral therapy (ART).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1-infection
CountriesSouth Africa
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartJun 2022
Primary CompletionJan 2025
TodayJul 2026
First PostedMar 16, 2022
Enrollment StartJun 9, 2022
Primary CompletionJan 16, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 4.3 years ago
Interventions
Vesatolimoddrug
Administered orally
VRC07523LSbiological
Administered intravenously
CAP256V2LSbiological
Administered intravenously